IMPDH1 Protein

IMPDH1 Protein

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">IMPDH1 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Inosine Monophosphate Dehydrogenase 1</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>IMPDH1</td></tr>
<tr><td><strong>Gene ID</strong></td><td>3616</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P20839">P20839</a></td></tr>
<tr><td><strong>PDB ID</strong></td><td>1JCN, 1B3R, 1ME8, 2CVD</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>55.4 kDa (per subunit)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm</td></tr>
<tr><td><strong>Protein Family</strong></td><td>IMPDH family, TIM barrel superfamily</td></tr>
<tr><td><strong>Expression</strong></td><td>Ubiquitous, highest in retina and brain</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/leukemia" style="color:#ef9a9a">Leukemia</a>, <a href="/wiki/neuroinflammation" style="color:#ef9a9a">Neuroinflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">10 edges</a></td>
</tr>
</table>
</div>

Overview

IMPDH1 Protein

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">IMPDH1 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Inosine Monophosphate Dehydrogenase 1</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>IMPDH1</td></tr>
<tr><td><strong>Gene ID</strong></td><td>3616</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/P20839">P20839</a></td></tr>
<tr><td><strong>PDB ID</strong></td><td>1JCN, 1B3R, 1ME8, 2CVD</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>55.4 kDa (per subunit)</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm</td></tr>
<tr><td><strong>Protein Family</strong></td><td>IMPDH family, TIM barrel superfamily</td></tr>
<tr><td><strong>Expression</strong></td><td>Ubiquitous, highest in retina and brain</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/autoimmune" style="color:#ef9a9a">Autoimmune</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/leukemia" style="color:#ef9a9a">Leukemia</a>, <a href="/wiki/neuroinflammation" style="color:#ef9a9a">Neuroinflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">10 edges</a></td>
</tr>
</table>
</div>

Overview

IMPDH1 (Inosine Monophosphate Dehydrogenase 1) is a crucial enzyme in the purine nucleotide biosynthesis pathway that catalyzes the NAD-dependent oxidation of inosine monophosphate (IMP) to xanthosine monophosphate (XMP), representing the rate-limiting step in GTP synthesis. This enzyme is essential for de novo purine nucleotide synthesis and is particularly important in cells with high proliferative or metabolic demands, including [neurons](/entities/neurons) during development, synaptic activity, and photoreceptor survival. [@natsumeda2008]

IMPDH1 exists as a tetramer, with each subunit containing a TIM barrel catalytic domain and a CBS (cystathionine β-synthase) domain pair that regulates enzyme activity through allosteric mechanisms. The enzyme requires flavin adenine dinucleotide (FAD) as a cofactor for its catalytic activity. Mutations in IMPDH1 cause retinitis pigmentosa, a progressive retinal degeneration leading to childhood-onset blindness, highlighting the protein's critical role in photoreceptor survival. Beyond retinal disease, IMPDH1 dysregulation has been implicated in [Huntington's disease](/diseases/huntingtons), [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and various cancers, making it a therapeutic target for both neurodegenerative conditions and oncology. [@hedstrom2009]

Structure and Catalytic Mechanism

Domain Architecture

IMPDH1 is a tetrameric enzyme composed of four identical subunits, each approximately 55 kDa. Each monomer contains two distinct structural domains:

N-terminal catalytic domain: The larger domain adopts the TIM barrel fold (β8α8), which contains the active site. The catalytic domain includes:

• IMP binding site located at the barrel's C-terminal end
• NAD binding pocket adjacent to the IMP site
• Flavin adenine dinucleotide (FAD) cofactor binding site
• Catalytic residues including Cys331, Asp360, and His395

• Mediate tetramer formation through intersubunit interactions
• Respond to metabolite signals (ATP, GTP, SADENYL)
• Modulate enzymatic activity through allosteric regulation
• The CBS domains sense cellular energy status and adjust IMPDH activity accordingly

Catalytic Mechanism

The IMPDH-catalyzed reaction proceeds through a two-step mechanism:

The reaction can be summarized as:
IMP + NAD⁺ + H₂O → XMP + NADH + H⁺

Key catalytic features include:

• Cys331 acts as the nucleophile that attacks IMP
• The reaction proceeds via a covalent enzyme-IMP intermediate
• FAD facilitates electron transfer during catalysis
• Product release is the rate-limiting step under physiological conditions

Normal Function in Neurons

Purine Nucleotide Biosynthesis

IMPDH1 plays a fundamental role in cellular metabolism by catalyzing the rate-limiting step in de novo GTP synthesis. The purine biosynthesis pathway produces IMP through a series of ten enzymatic reactions, and IMPDH1 converts IMP to XMP, which is subsequently converted to GMP by GMP synthetase. GMP can then be converted to GTP through the action of nucleoside diphosphate kinase.

GTP serves as:

• A building block for DNA and RNA synthesis
• An energy currency molecule (GTP/GDP cycle)
• A substrate for protein synthesis (GTP-bound translation factors)
• A signaling molecule for GTPases (small G proteins)
• A precursor for cyclic nucleotides (cGMP)

Neuronal GTP Synthesis

In neurons, IMPDH1-mediated GTP synthesis is particularly critical for several neuronal-specific functions:

Synaptic plasticity: GTP is essential for the function of small GTPases (Ras, Rho, Rab families) that regulate:

• Dendritic spine formation and maintenance
• Actin cytoskeleton dynamics
• Vesicle trafficking at synapses
• Long-term potentiation (LTP) and depression (LTD) [@ferrer2015]

• Initiation factor eIF2 (requires GTP)
• Ribosome assembly
• Polypeptide elongation

• G-protein coupled receptor signaling
• NMDA receptor modulation
• Voltage-gated calcium channel regulation

Energy Metabolism

Neurons have particularly high energy demands due to:

• Resting membrane potential maintenance
• Action potential propagation
• Synaptic vesicle cycling
• Dendritic integration

• Mitochondrial function (GTP for TCA cycle enzymes)
• Cytoskeletal motor proteins (kinesin/dynein ATP/GTP use)
• Cellular homeostasis

Retinal Photoreceptors

IMPDH1 is highly expressed in retinal photoreceptors, where mutations cause retinitis pigmentosa. Photoreceptors have extraordinarily high metabolic demands due to:

• Continuous photopigment regeneration
• Dark current maintenance
• Synaptic transmission with bipolar cells

Role in Neurodegenerative Diseases

Alzheimer's Disease

IMPDH1 dysregulation has been implicated in [Alzheimer's disease](/diseases/alzheimers-disease) through multiple mechanisms:

Purine metabolism alterations: Several studies have documented changes in purine metabolism in AD brains:

• Decreased GTP levels in AD brain tissue [@li2018]
• Altered IMPDH expression in AD models
• Relationship between purine metabolism and amyloid pathology

• Small GTPases regulate AMPA receptor trafficking
• Actin dynamics require GTP-bound proteins
• Vesicle cycling depends on GTPases

• IMPDH inhibitors reduce amyloid-beta toxicity in cellular models [@park2021]
• GTP restoration may improve synaptic function
• Purine precursor supplementation shows promise in preclinical studies

Parkinson's Disease

Evidence links IMPDH1 to [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis:

Dopaminergic neuron vulnerability: The high metabolic demands of dopaminergic neurons make them particularly susceptible to:

• Mitochondrial dysfunction
• Energy deficits
• Oxidative stress

• Reduced IMPDH activity in dopaminergic cells [@zhang2019]
• Connection to mitochondrial complex I deficiency
• Relationship to alpha-synuclein aggregation

• Enhancing GTP synthesis may protect dopaminergic neurons
• Combination approaches with mitochondrial targets

Huntington's Disease

IMPDH1 has been directly implicated in [Huntington's disease](/diseases/huntingtons):

GTP depletion: Mutant huntingtin protein:

• Impairs cellular energy metabolism
• Reduces GTP synthesis capacity
• Causes progressive neuronal dysfunction

• Improves neuronal survival in HD models [@liao2016]
• May address energy deficit in affected neurons

Amyotrophic Lateral Sclerosis (ALS)

New research links purine metabolism to [ALS](/diseases/amyotrophic-lateral-sclerosis):

Metabolic dysfunction: ALS motor neurons show:

• Altered nucleotide metabolism [@sundaram2023]
• Impaired GTP synthesis
• Energy deficit

• Metabolic support for motor neurons
• Protection against excitotoxicity

Therapeutic Approaches

IMPDH Inhibitors

Several IMPDH inhibitors have been developed for clinical use:

Mycophenolic acid: The classic IMPDH inhibitor

• Used as an immunosuppressant (CellCept)
• Inhibits T and B cell proliferation
• Potential for neuroprotection in certain contexts
• Limitations: systemic immunosuppression

• Induces differentiation in cancer cells
• Has been studied in neurodegenerative models
• Shows potential for ALS treatment

• Being explored for neuroprotection
• May have benefits in PD models

GTP Precursors

An alternative approach involves supplementing GTP precursors:

Inosine: A purine nucleoside that can be converted to IMP

• Increases GTP levels in cells
• Being investigated for PD treatment
• Clinical trials ongoing for safety and efficacy

• Activates AMPK
• Improves nucleotide metabolism
• Shows promise in neurodegenerative models

Gene Therapy Approaches

Future therapeutic directions include:

• Viral vector-mediated IMPDH1 delivery
• CRISPR-based gene correction for RP mutations
• Small molecule allosteric activators

Genetics and Mutations

Retinitis Pigmentosa Mutations

Over 40 IMPDH1 mutations have been associated with retinitis pigmentosa:

• Dominant and recessive inheritance patterns
• Loss-of-function mechanisms
• Photoreceptor-specific vulnerability
• Variable age of onset and progression

Polymorphisms and Disease Risk

Genetic variations in IMPDH1 may influence:

• Cancer susceptibility
• Neurodegenerative disease risk
• Drug response

Interactions and Pathway Membership

Protein Interactions

IMPDH1 interacts with several cellular proteins:

• GMP synthetase (next step in pathway)
• Mdm2 (p53 regulation)
• RB tumor suppressor
• Ribosomal proteins

Pathway Membership

IMPDH1 is central to several pathways:

• De novo purine biosynthesis: Primary enzyme in GTP synthesis
• Nucleotide metabolism: Central carbon-nitrogen metabolism
• Energy metabolism: GTP as energy currency
• Signaling pathways: Downstream of mTOR and AMPK

Animal Models

Knockout Studies

IMPDH1 knockout mice are embryonic lethal, demonstrating essential function:

• Impaired cell proliferation
• Developmental arrest
• Mitochondrial dysfunction

Conditional Knockouts

Tissue-specific knockouts reveal:

• Photoreceptor degeneration (retina knockout)
• Neuronal dysfunction (brain knockout)
• Lymphocyte defects (immune system)

Biomarker Potential

IMPDH activity may serve as a biomarker:

• Decreased IMPDH in neurodegenerative disease
• Correlates with disease severity
• Potential for diagnostic or monitoring applications

Research Directions

Current research areas include:

See Also

• [IMPDH1 Gene](/genes/impdh1)
• [Purine Metabolism](/mechanisms/purine-metabolism)
• [Retinitis Pigmentosa](/diseases/retinitis-pigmentosa)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Huntington's Disease](/diseases/huntingtons)
• [GTPase Signaling](/mechanisms/gtpase-signaling)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [Nucleotide Metabolism](/mechanisms/nucleotide-metabolism)

External Links

• [UniProt: P20839 - IMPDH1 Human](https://www.uniprot.org/uniprot/P20839)
• [PDB: Human IMPDH1 Structures](https://www.rcsb.org/structure/1JCN)
• [NCBI Gene: IMPDH1 (3616)](https://www.ncbi.nlm.nih.gov/gene/3616)
• [OMIM: IMPDH1 Retinitis Pigmentosa](https://www.omim.org/entry/613673)

References

Clinical Studies and Trials

Current Clinical Trials

Several clinical trials are investigating purine metabolism modulation:

Inosine Supplementation Trials:

• Phase II trials for Parkinson's disease
• Safety and efficacy evaluation
• Biomarker endpoints (urate levels)
• Ongoing at multiple centers

• Investigational use in ALS
• Phase I/II trials planned
• Immunomodulation and neuroprotection

Biomarker Studies

IMPDH activity as a biomarker:

• Reduced activity in PD patient lymphocytes
• Correlation with disease progression
• Potential for early detection
• Non-invasive measurement possible

Comparative Biology

IMPDH Isoforms

Humans express two IMPDH isoforms:

• IMPDH1: Predominantly in retina, brain, and immune cells
• IMPDH2: Ubiquitous, highly expressed in proliferating cells

• Different tissue distribution
• Distinct regulatory mechanisms
• Isoform-specific functions in disease

Evolutionary Conservation

IMPDH is highly conserved across:

• Bacteria (bacterial IMPDH differs in structure)
• Yeast (two isoforms, IMPDH1 and IMPDH2)
• Mammals (conserved domain structure)
• Plants (dual localization: cytosol and plastids)

Pathophysiological Mechanisms

Oxidative Stress

IMPDH dysfunction contributes to oxidative stress:

• NADPH depletion reduces antioxidant capacity
• GTP deficiency impairs redox regulation
• Mitochondrial dysfunction ensues

Energy Failure

The ATP/GTP energy crisis in neurodegeneration:

• IMPDH impairment reduces GTP synthesis
• Energy deficit affects neuronal function
• Contributes to cell death cascades

DNA/RNA Synthesis Defects

Reduced purine nucleotides affect:

• DNA repair capacity
• RNA synthesis and processing
• Mitochondrial DNA maintenance

Protein Homeostasis

GTP-dependent processes affected:

• Translation initiation and elongation
• Protein folding (GTP chaperones)
• Degradation pathways

Diagnostic and Prognostic Applications

Laboratory Diagnostics

IMPDH activity measurement:

• Blood lymphocyte assay
• Fibroblast culture analysis
• Postmortem brain tissue studies

Prognostic Markers

IMPDH alterations may predict:

• Disease progression rate
• Treatment response
• Survival outcomes

Differential Diagnosis

Purine metabolism analysis helps distinguish:

• Different neurodegenerative conditions
• Disease subtypes
• Sporadic vs. familial cases

Future Directions and Challenges

Challenges in Drug Development

Key challenges include:

Emerging Research Areas

Future directions encompass:

Unanswered Questions

Critical questions remaining:

• Primary cause vs. consequence of IMPDH dysfunction
• Tissue-specific vulnerability mechanisms
• Optimal intervention timing
• Biomarker-guided treatment selection